Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1

Cocaine-Related Disorders Clinical Trial

Official title:

Cocaine Relapse Prevention II

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00094315
• Other study ID #: NIDA-CTO-0014-1
• Status: Active, not recruiting
• Phase: Phase 1
• First received: October 15, 2004
• Last updated: January 10, 2017
• Start date: September 2004
• Est. completion date: July 2005

Study information

• Verified date: September 2005
• Source: National Institute on Drug Abuse (NIDA)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To study of classical conditioning mechanisms associated with arousal, craving and cocaine use.

Description:

This is a single-site, double-blind, placebo-controlled crossover study of classical conditioning mechanisms associated with arousal, craving and cocaine use.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 16
• Est. completion date: July 2005
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Be English-speaking volunteers who are cocaine dependent

• Be non-treatment seeking at the time of the study

• Meet DSM-IV criteria for cocaine dependence

• Have ECG showing normal sinus rhythm, normal conductivity, and non clinically significant arrhythmias

• Females must provide a negative pregnancy test and agree to use birth control

• Have baseline laboratory tests within normal limits

Exclusion Criteria:

• Please contact site for more information

Study Design

N/A

Related Conditions & MeSH terms

• Cocaine-Related Disorders

Intervention

Drug:
• Cocaine (IV)

Locations

Country	Name	City	State
United States	University of Texas Health Science Center	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Stimulated and non-stimulated craving
Primary	Cocaine assessment